Format

Send to

Choose Destination
See comment in PubMed Commons below
Chem Biol. 2012 Jan 27;19(1):51-9. doi: 10.1016/j.chembiol.2011.12.011.

Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity.

Author information

1
Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL 33458, USA. tburris@scripps.edu

Abstract

The nuclear receptor (NR) superfamily is composed of 48 members in humans and includes receptors for steroid hormones, thyroid hormone, various lipids and oxysterols. This superfamily has been a rich source of drug targets for myriad diseases including inflammation, cancer, and metabolic disorders. Approximately half of the superfamily have well characterized natural ligands whereas the remaining receptors are considered orphan receptors and remain a focus of a number of investigators assessing their ability to be regulated by ligands. Here, we review recent discoveries that yield important insight into the druggability of three orphan nuclear receptors: the retinoic acid receptor-like orphan receptors (RORs), peroxisome proliferator-activated receptor γ (PPARγ), and liver receptor homolog-1 (LRH-1).

PMID:
22284354
PMCID:
PMC3269034
DOI:
10.1016/j.chembiol.2011.12.011
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center